|Bid||0.00 x 1800|
|Ask||0.00 x 2200|
|Day's Range||11.90 - 12.57|
|52 Week Range||8.86 - 33.97|
|Beta (5Y Monthly)||1.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 03, 2022 - Aug 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.81|
Subscribe to Yahoo Finance Plus to view Fair Value for AUPH
Aurinia (AUPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Shares of the commercial-stage biopharma Aurinia Pharmaceuticals (NASDAQ: AUPH) rose by as much as 13.7% during Friday's trading session. This time around, Japanese drug manufacturer Otsuka Holdings is rumored to be considering a bid, according to a report posted on the subscription-based Betaville website and subsequently circulated on Twitter. Aurinia, for its part, has not commented on this takeover speculation.
VICTORIA, British Columbia, June 06, 2022--Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)